Revive Adrenaline Auto-injector: Industrial Research

肾上腺素自动注射器(AAI)是为容易发生严重过敏的人开的，这会使他们面临过敏反应的风险--一种危及生命的过敏反应。尽管医学建议总是随身携带注射器，但我们的用户研究表明：1.人们携带的注射器数量几乎没有他们应该携带的那么多。由于肾上腺素是唯一已知的预防因过敏而死亡的药物，因此不接受肾上腺素的过敏反应是导致死亡的最大常见因素。女性是一个值得关注的关键领域，因为目前的针头长度并不能保证在这种患者群体中肌肉内分娩。Revive是一个新的人工智能概念，作为皇家艺术学院(RCA)的毕业设计而开发。在2020年1月的创新英国智能拨款中成功实现REVIVE自动注射器的技术可行性后，我们可以开展实验室规模的实验评估活动，评估概念验证和安全性，并在这个拟议的项目中探索潜在的生产机制。该项目提案是为了验证对AAI监管要求的初步遵守，并将特别关注供应链(在实验室规模的模型中验证集装箱封口完整性的无菌灌装和塞子的概念)。我们还将进行一项用户研究，量化我们的设备与现有产品相比的相对增长。该设备以患者为中心设计，其信用卡大小使其易于携带，其形式使其谨慎地适合患者的生活。这些措施前所未有地结合在一起，抵消了已确定的问题，即规模太大，实际上无法持续进行。与目前市场上的大多数产品不同，Revive采用了英国复苏委员会建议的更长针头的指导方针，以减少过敏管理系统中的性别差异。REVIVE通过重新检查应该如何为人工智能设计注射器来实现这一点。专有的针头注射系统概念已获得InnovationRCA的支持，并在英国申请专利(知识产权局已将申请转移到授权)。该公司目前正在InnovationRCA孵化，这是MedCity的试点社区计划和NHS创新服务Beta计划的一部分。它得到了《旗帜晚报》和《蓝图》杂志的宣传，还获得了全球毕业展、英国发明展和胚胎风险投资公司的支持。

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show:1. People do not carry them nearly as much as they should2. Not receiving adrenaline for an anaphylactic reaction is the biggest common factor in fatalities as adrenaline is the only drug known to prevent death due to anaphylaxis3. Women are a key area of concern as current needle lengths do not guarantee intramuscular delivery in this patient populationRevive is a new AAI concept developed as a graduation project at the _Royal College of Art (RCA)_. After successful technical feasibility of the Revive auto-injector in the Innovate UK Smart Grant January 2020 we can undertake activities for experimental evaluation at laboratory scale, evaluate proof of concept and safety, and explore potential production mechanisms in this proposed project. This project proposal is to validate the preliminary adherence to the regulatory requirements of an AAI and particular attention will be paid towards the supply chain (proof of concept aseptic filling and stoppering for container closure integrity in a lab-scale model). We will also conduct a user study to quantify comparative increase of our device being carried vs. existing products.Designed with the patient at its centre, its credit card size makes it easy to carry and its form makes it discreetly fit within a patient's life. These combine like never before to counteract the identified problems of being too large to practically carry continuously. Revive, unlike most current offerings in the market, incorporates the UK Resuscitation Council's recommended guidelines for a longer needle to reduce the gender disparity in allergy management systems. Revive achieves this through a fresh examination of how a syringe should be designed for an AAI. The proprietary needle injection system concept has been awarded InnovationRCA's support and is patent pending in the UK (Intellectual property office has moved application towards grant).The company is currently incubated at InnovationRCA, Medcity's Pilot Community Program and part of NHS Innovation Service Beta program. It has received publicity from _The Evening Standard_ & _Blueprint magazine_ and also won support from the Global Grad Show, British Invention Show and Embryo Ventures.